Technology | October 03, 2014

Gore Receives FDA Approval for Endovascular Treatment of In-stent Restenosis with the Gore Viabahn Endoprosthesis

Innovative treatment offers long-term solution for ISR

W.L. Gore FDA Approval Gore Viabahn Endoprosthesis

October 3, 2014 — W. L. Gore & Associates Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the Gore Viabahn Endoprosthesis for interventional treatment of in-stent restenosis in the superficial femoral artery (SFA). Now indicated for the treatment of failed bare metal stents (BMS) in the SFA, the Gore Viabahn device has more vascular indications supported by more level 1 clinical trials than any other self-expanding peripheral stent or stent-graft.

In-stent restenosis or reocclusion occurs in a significant number of patients over the course of one year after bare metal stenting, and these rates are highly dependent on the severity of disease. Treatment options for in-stent restenosis include angioplasty, repeat stenting with another BMS, and surgical bypass. The Gore Viabahn device changes the current treatment paradigm for in-stent restenosis by re-lining the failed BMS and adjacent diseased vessel, providing a long-term physical barrier that extends the life of the intervention.

The safety and efficacy of the Gore Viabahn device in this indication was supported by the randomized RELINE Clinical Study, in which the lesions in both arms of the study averaged more than 17 cm in length. The study found that the device is statistically superior in target lesion primary patency than percutaneous transluminal angioplasty, or PTA, which is the most common frontline interventional treatment of in-stent restenosis.

The RELINE Clinical Study found that:

  • Subjects in the Gore Viabahn device arm of the RELINE trial were approximately three times less likely than those in the PTA arm to require a target lesion revascularization (TLR) after one year.
  • After 12 months, the Gore Viabahn Endoprosthesis showed a primary patency of 74.8 percent, more than 45 percent higher than PTA.
  • With the longest available 25 cm stent-graft, heparin surface, and ePTFE liner, the Gore Viabahn Device is a long-lasting solution for treatment of failed bare stents.

“The treatment of failed bare metal stents has long been a perplexing problem for vascular specialists, in which only a few treatments are FDA-approved and limited compelling clinical data exist. This new indication for the Gore device and the accompanying data from the RELINE trial provide physicians with the means to intervene confidently on a failed bare metal stent, extending the life of the intervention and improving patient outcomes,” said Peter A. Soukas, M.D., assistant professor of medicine, Brown Medical School.

The Gore Viabahn Endoprosthesis is the lowest profile, most flexible, self-expanding stent-graft available. It is the only stent-graft to receive approval for the SFA (de novo, restenotic, and in-stent restenotic disease), iliac artery, and arteriovenous access revision. The device is constructed with a durable, reinforced, biocompatible, expanded ePTFE liner and attached to an external nitinol stent structure. The ePTFE luminal surface of the Gore Viabahn device features the CBAS Heparin Surface intended to provide sustained thromboresistance.

For more information: www.goremedical.com

Related Content

FDA Classifies Previous Endologix AFX Safety Notice as Class I Recall
News | Endovascular Aortic Repair | October 08, 2018
Endologix Inc. received notice that the U.S. Food and Drug Administration (FDA) has classified a voluntary recall...
The Gore TAG stent graft used in TEVAR aortic repair procedures for aneurysms.

The Gore TAG stent graft used for endovascular aortic aneurysm repair procedures.

Feature | Endovascular Aortic Repair | February 05, 2018 | Andrei Churyla, M.D., S. Chris Malaisrie, M.D.
Here are several considerations for physicians when choosing...
Endologix Receives IDE Approval for EVAS2 Confirmatory Clinical Study
News | Endovascular Aortic Repair | October 19, 2017
Endologix Inc. received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA...
New Paper Highlights Success of Advanced Treatments in Complex Aortic Aneurysm Repair
News | Endovascular Aortic Repair | May 23, 2017
Significant success has been achieved in treating complex proximal aneurysms using a combination of fenestrated and...
abdominal aortic aneurysm, AAA, gender differences, women vs. men, endovascular repair, Journal of Vascular Surgery study
News | Endovascular Aortic Repair | April 05, 2017
Following repair of abdominal aortic aneurysms (AAA), women appear to have more unfavorable outcomes than men in terms...
Beaumont Hospital, Michigan, endovascular aortic repair, EVAR, conscious sedation
News | Endovascular Aortic Repair | July 08, 2016
Kirk Schoenherr, 56, of Clinton Township, Mich., recently became just the second patient at Beaumont Hospital, Royal...
Aptus Endosystems, Medtronic, acquisition, Heli-FX, Thoracic EndoAnchor, EVAR

Heli-FX image courtesy of Aptus Endosystems

News | Endovascular Aortic Repair | July 02, 2015
Medtronic plc announced it has acquired the assets of Aptus Endosystems Inc., a privately held medical device company...
Overlay Init